Navigation Links
Sequenom Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Date:3/2/2011

SAN DIEGO, March 2, 2011 /PRNewswire/ -- Sequenom, Inc. (Nasdaq: SQNM), today announced the awards of non-qualified stock option grants for a total of 74,450 shares of common stock for six new employees under the company's New Hire Equity Incentive Plan.

(Logo:  http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

Of these shares, 14,450 have an exercise price of $6.14, which was equal to the closing price of Sequenom's common stock on February 28, and 60,000 have a price of $6.39, the closing price of its common stock on February 15, the dates the options were granted. These options will vest over the course of four years, with 25% vesting on the one-year anniversary of the grant dates and ratably monthly thereafter, subject to continued service through the applicable vesting dates. The stock options have a ten year term, and are granted as an inducement grant to the new employees entering into employment with Sequenom pursuant to Section 5635(c)(4) of the NASDAQ Marketplace Rules.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a website at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom website to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

SEQUENOM® is a trademark of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company's commitment to improving healthcare through revolutionary genetic analysis solutions, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company's ability to develop and commercialize new technologies and products, particularly new technologies such as genetic analysis platforms, noninvasive prenatal diagnostics and laboratory developed tests, reliance upon the collaborative efforts of other parties, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, ongoing litigation and investigations and other risks detailed from time to time in the Company's most recent

Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sequenom CMM Commences Pivotal Clinical Validation Study for Its SensiGene Trisomy 21 Laboratory Developed Test
2. Sequenom to Present at Two Financial Conferences in November
3. Sequenom Announces Date of Second Quarter 2010 Financial Results and Conference Call
4. Sequenom to Present at the Jefferies 2010 Global Life Sciences Conference
5. Sequenom Announces Final Approval of Settlement in Class Action Securities Lawsuit
6. Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results
7. Sequenom Announces Launch of SensiGene Fetal(XY) (Fetal Sex Determination) Test
8. Sequenom Announces Addition to Clinical Advisory Board
9. Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit
10. Sequenom Announces Paul Maier to Become Interim Chief Financial Officer
11. University of Michigan Study Shows SEQUENOMs MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... as president, effective Aug. 7, 2017. ... to pursue other interests and will serve as president emeritus ... has served us in multiple leadership roles since he joined ... 2015 and has provided decisive, strategic leadership which continues to ...
(Date:8/4/2017)... CINCINNATI , Aug. 3, 2017  Agragen, ... science company active in the biopharmaceutical, nutraceutical, and ... its development of its lead drug candidates, AGR131.  ... a proinflammatory cytokine from the blood of patients ... psoriasis, and inflammatory bowel disease. ...
(Date:8/2/2017)... Ore. , Aug. 2, 2017  Life Flight Network ... Agreement. The agreement improves patient care and operational efficiency for ... Springfield , Cottage Grove , ... level medical transportation. PeaceHealth and Life Flight Network work collaboratively ... available during transport, or when a time sensitive emergency exists. ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... More than 20,000 pairs of shoes made their ... to an ambitious venture that conjoined the passions of an NBA star, a Liberty ... Liberty community. These shoes will save lives from the rampant infections transmitted through the ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... a highly specialized asset-light logistics provider of complex transport solutions for mission-critical ... to purchase Unitrans International Corporation, a division of Roadrunner Transportation Systems, Inc. ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... of “Vision & Hearing,” advocating for active, healthy lifestyles and highlighting the importance ... for individuals with hearing impairments and shares the latest innovations in hearing aid ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... handheld devices. Through an educational webinar, they will present the line of epMotion ... to learn how easy you can automate everyday pipetting tasks. , Ideal for ...
(Date:8/18/2017)... ... August 18, 2017 , ... Hernandez Insurance ... to communities throughout the greater DC region, is inaugurating a “New Leash On ... local animals and training them to be companions for veterans in need. , ...
Breaking Medicine News(10 mins):